{
    "nctId": "NCT02886962",
    "officialTitle": "Study of the Benefit / Risk Ratio of Oral Anticoagulation in Hemodialysis Patients With Atrial Fibrillation",
    "inclusionCriteria": "* Adult patients (\u2265 18 years)\n* Patient on hemodialysis treatment for at least 1 month\n* Patient with a history of, or presenting a new episode of atrial fibrillation (either permanent or paroxysmal).\n* Patient with a CHADS2VASC score \u22652\n* Patient with high risk of bleeding as defined by (1) HASBLED score \u22653 OR (2) HASBLED \u2265 CHADS2VASC score, OR (3) recent history of severe bleeding (type 3a, 3b, 3c), particularly cerebral or gastrointestinal, OR (4) prior recurrent (\\>2) history of falls.\n* Patient capable of understanding information about the study and of giving his/her consent\n* Patient informed of the preliminary medical exam results\n* Patient with healthcare insurance\n* Written consent signed\n* Must have minimum age of 18 Years",
    "exclusionCriteria": "* Formal indication to oral anticoagulation beside atrial fibrillation (mechanic heart valves, recurrent thrombophlebitis, antiphospholipid syndrome)\n* Life expectancy \\< 6 months (e.g., terminal cancer)\n* Live donor transplantation scheduled within 6 months\n* Pregnancy (\u03b2-HCG blood-based assay)or nursing (lactating) women\n* Women of child bearing potential, unless they are using an effective method of birth control\n* Patient under legal guardianship\n* Patients under law protection\n* Known hypersensibility to coumadin or indoine derivatives or to any excipients (CI to oral AVK)\n* Severe liver failure (CI to oral AVK)"
}